Skip to main content
. 2016 Aug 5;31(1):115–122. doi: 10.1038/leu.2016.186

Table 1. Patient demographics and baseline disease characteristics.

  1 Prior line
2 Prior lines
  Kd (n=232) Vd (n=232) Kd (n=232) Vd (n=233)
Age, median years (range) 66.0 (36.0–89.0) 63.5 (39.0–88.0) 64.0 (35.0–89.0) 66.0 (30.0–86.0)
ECOG PS, n (%)        
 0 110 (47.4) 131 (56.5) 111 (47.8) 101 (43.3)
 1 104 (44.8) 92 (39.7) 107 (46.1) 111 (47.6)
 2 18 (7.8) 9 (3.9) 14 (6.0) 21 (9.0)
         
Cytogenetic risk by FISH at study entry, n (%)
 High risk 44 (19.0) 53 (22.8) 53 (22.8) 60 (25.8)
 Standard risk 149 (64.2) 144 (62.1) 135 (58.2) 147 (63.1)
 Unknown/missing 39 (16.8) 35 (15.1) 44 (19.0) 26 (11.1)
         
Creatinine clearance, n (%)
 <30 ml/min 14 (6.0) 17 (7.3) 14 (6.0) 11 (4.7)
 30 to <50 ml/min 26 (11.2) 27 (11.6) 31 (13.4) 44 (18.9)
 50 to <80 ml/min 97 (41.8) 85 (36.6) 89 (38.4) 92 (39.5)
 ⩾80 ml/min 95 (40.9) 103 (44.4) 98 (42.2) 86 (36.9)
         
ISS stage, n (%)
 Stage 1 109 (47.0) 115 (49.6) 103 (44.4) 90 (38.6)
 Stage 2 68 (29.3) 62 (26.7) 70 (30.2) 89 (38.2)
 Stage 3 55 (23.7) 55 (23.7) 59 (25.4) 54 (23.2)
         
Prior therapy, n (%)
 Bortezomib 96 (41.4) 101 (43.5) 154 (66.4) 151 (64.8)
 Lenalidomide 51 (22.0) 47 (20.3) 126 (54.3) 130 (55.8)

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; FISH, fluorescence in situ hybridization; ISS, International Staging System; Kd, carfilzomib and dexamethasone; Vd, bortezomib and dexamethasone.